Why can't these pharmaceutical companies make small profits but quick turnover? Because most targeted drugs are used by patients with advanced cancer, and the life span of these patients is very short, they have to change their medicines in the case of drug resistance (which is why many drugs can still be free after taking 1.5 million or how much money, because many people can't be free for a long time, or develop drug resistance), so the total number of drug buyers is constant on a more suitable basis (the number is not too large, so it is "multi-selling". From the pharmacological point of view, targeted drugs can selectively reach target tissues, target organs and target cells in specific parts with the help of carriers, ligands or antibodies, with high bioavailability, high therapeutic index and little side effects, which is a new dosage form developed in recent years. Especially in cancer treatment, compared with other drug formulations, it has incomparable advantages and can minimize the side effects of anticancer drugs on normal tissues and organs of the body.
It is normal that the price is high. The research and development cycle of new drugs is long, the investment is large, the risk is high, the targeted preparation has high technology content, and it involves the protection of imported patents, so the price is naturally high. But the efficacy of targeted drugs is beyond doubt.